Overcoming market access barriers to high-value drugs
How can you breakthrough the market access barriers that face high-value oncology and immunotherapy products in the EU5 and US?
Pharma faces unprecedented demands from payers, patients, HTAs and KOLs to prove value and utility for high-cost therapies in key conditions such as Cancer, Multiple Sclerosis, HIV and Rheumatoid Arthritis. Get it wrong, and you won’t achieve formulary listing, reimbursement or an optimum price. Further, there is a trend in key markets to empower local decision making, radically increasing the number of stakeholder touch points. In a time of budget constraint, how can companies up their game to meet the growing challenges?
This report is available for immediate download after purchase -- buy your report now.
In Overcoming Market Access Barriers to High-value Drugs senior industry experts from leading pharma companies address 7 key barriers and propose actionable solutions to ensure market access success. Buy the report now.
Report available for immediate download -- place your order today
Report available for immediate download -- place your order now
“The value story for payers and policymakers for your product [is important]. Often, companies have the challenge of not having local data available. They must determine how to work with local stakeholders to build a credible value story for their medicine.”
Chetak Buaria,
Global Head of Commercial Excellence, Merck KGaA
Anonymous,
Global Market Access Manager at a leading biotechnology company
“To address the patient preference aspect of market access barriers, you must develop strong relationships with your patient advocacy groups so that the patients have accurate information available to them about your product from independent sources. There are highly active patient organisations involved in particular cancer types, where patients are very aware of their disease and its implications. You also need to look at what endpoints are important to patients so that they will get behind you and support, argue for, and champion the access to your product.”
Nicola Redfern,
Previously Director of Oncology Market Access at Baxalta and
Director of Market Access and Corporate Affairs at Celgene
“You want to keep on building on the data and the value that you offer over the course of the product lifecycle. What you need to do is determine how you can work with select KOLs to build incremental data, since not everything will be available when you launch a product.”
Chetak Buaria,
Global Head of Commercial Excellence, Merck KGaA
Critical insights from these and many other respected experts available for immediate download —place your order here
Report available for immediate download — place your order now
This critical intelligence is available for immediate download — order your copy now
Need more information? Contact a consultant for an executive summary and sample pages from the report.
Overcoming market access barriers to high-value drugs
How can you breakthrough the market access barriers that face high-value oncology and immunotherapy products in the EU5 and US?
Pharma faces unprecedented demands from payers, patients, HTAs and KOLs to prove value and utility for high-cost therapies in key conditions such as Cancer, Multiple Sclerosis, HIV and Rheumatoid Arthritis. Get it wrong, and you won’t achieve formulary listing, reimbursement or an optimum price. Further, there is a trend in key markets to empower local decision making, radically increasing the number of stakeholder touch points. In a time of budget constraint, how can companies up their game to meet the growing challenges?
This report is available for immediate download after purchase -- buy your report now.
In Overcoming Market Access Barriers to High-value Drugs senior industry experts from leading pharma companies address 7 key barriers and propose actionable solutions to ensure market access success. Buy the report now.
Report available for immediate download -- place your order today
Report available for immediate download -- place your order now
Each industry expert has been carefully selected for their practical experience and detailed knowledge of current US/EU5 market access challenges.
“The value story for payers and policymakers for your product [is important]. Often, companies have the challenge of not having local data available. They must determine how to work with local stakeholders to build a credible value story for their medicine.”
Chetak Buaria,
Global Head of Commercial Excellence, Merck KGaA
Anonymous,
Global Market Access Manager at a leading biotechnology company
“To address the patient preference aspect of market access barriers, you must develop strong relationships with your patient advocacy groups so that the patients have accurate information available to them about your product from independent sources. There are highly active patient organisations involved in particular cancer types, where patients are very aware of their disease and its implications. You also need to look at what endpoints are important to patients so that they will get behind you and support, argue for, and champion the access to your product.”
Nicola Redfern,
Previously Director of Oncology Market Access at Baxalta and
Director of Market Access and Corporate Affairs at Celgene
“You want to keep on building on the data and the value that you offer over the course of the product lifecycle. What you need to do is determine how you can work with select KOLs to build incremental data, since not everything will be available when you launch a product.”
Chetak Buaria,
Global Head of Commercial Excellence, Merck KGaA
Critical insights from these and many other respected experts available for immediate download —place your order here
Report available for immediate download — place your order now
This critical intelligence is available for immediate download — order your copy now
Need more information? Contact a consultant for an executive summary and sample pages from the report.
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved